AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines
Liyang Zhang(Integrated DNA Technologies (United States)), Christopher A. Vakulskas(Integrated DNA Technologies (United States))
Cited by 171
Related Papers
A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells
|Nature Medicine|2018|796
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
|New England Journal of Medicine|2025|272